Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | VSV-hIFNbeta-NIS |
Synonyms | |
Therapy Description |
VSV-hIFNbeta-NIS is oncolytic vesticular stomatitis virus engineered to express human interferon-beta (hIFN-beta) and sodium iodide symporter (NIS), which may inhibit tumor growth (PMID: 26712908, PMID: 22425894). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VSV-hIFNbeta-NIS | Voyager-V1|VV1 | VSV-hIFNbeta-NIS is oncolytic vesticular stomatitis virus engineered to express human interferon-beta (hIFN-beta) and sodium iodide symporter (NIS), which may inhibit tumor growth (PMID: 26712908, PMID: 22425894). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02923466 | Phase Ib/II | Avelumab + VSV-hIFNbeta-NIS VSV-hIFNbeta-NIS | Trial of Intratumoral Administration of Recombinant Vesicular Stomatitis Virus Monotherapy and in Combination With Avelumab in Patients With Refractory Solid Tumors | Completed | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03120624 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |